Detalhe da pesquisa
1.
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Cancer
; 126(6): 1264-1273, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860140
2.
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Cancer
; 124(2): 306-314, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28960265
3.
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Haematologica
; 102(4): 719-727, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28034990
4.
Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults.
Leuk Lymphoma
; 63(6): 1428-1435, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075985
5.
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
EJHaem
; 3(2): 434-442, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35846042
6.
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.
Lancet Haematol
; 7(2): e122-e133, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31837959
7.
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy.
Leukemia
; 34(11): 3050-3054, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32678290